Effect of statins on the risk of recurrent venous thromboembolism: A systematic review and meta-analysis

作者全名："Li, Ruihao; Yuan, Manqiu; Yu, Shixiong; Fu, Wenlong; Yu, Wu; Ling, Siying; Sun, Jianming; Chen, Yikuan"

作者地址："[Li, Ruihao; Yu, Shixiong; Fu, Wenlong; Yu, Wu; Ling, Siying; Sun, Jianming; Chen, Yikuan] Chongqing Med Univ, Dept Vasc Surg, Affiliated Hosp 2, 74 Linjiang Rd, Chongqing 400010, Peoples R China; [Yuan, Manqiu] Lanzhou Univ, Dept Lab Med, Hosp 1, 1 Western Donggang Rd, Lanzhou 730000, Peoples R China"

通信作者："Chen, YK (corresponding author), Chongqing Med Univ, Dept Vasc Surg, Affiliated Hosp 2, 74 Linjiang Rd, Chongqing 400010, Peoples R China."

来源：PHARMACOLOGICAL RESEARCH

ESI学科分类：PHARMACOLOGY & TOXICOLOGY

WOS号：WOS:000643653800015

JCR分区：Q1

影响因子：9.3

年份：2021

卷号：165

期号：　

开始页：　

结束页：　

文献类型：Review

关键词：Venous thromboembolism; Hydroxymethylglutaryl-CoA reductase inhibitors; Venous thrombosis; Pulmonary embolism; Mortality

摘要："Background: Recent studies have suggested that statins may be associated with a lower risk of recurrent venous thromboembolism (VTE). Methods: We systematically searched PubMed, Web of Science and Cochrane Library from inception until May 2020 to identify any eligible studies that reported the association between statin use and the risk of recurrent VTE, and conducted a comprehensive systematic review and meta-analysis (PROSPERO registration number: CRD42020190169) on this matter. Results: A total of 14 observational studies were included for qualitative review and 12 of them qualified for meta-analyses. The main meta-analysis found that statin use was associated with a lower risk of disease recurrence among patients with VTE (pooled adjusted HR: 0.76, 95% CI: 0.69-0.83), which was robust in sensitivity analyses and free of significant publication bias. Additionally, such association was present when restricting to periods after anticoagulation withdrawal (pooled adjusted HR: 0.78, 95% CI: 0.70-0.88) and when separately analyzing recurrent deep vein thrombosis (pooled adjusted HR: 0.71, 95% CI: 0.62-0.81) and recurrent pulmonary embolism (pooled adjusted HR: 0.80, 95% CI: 0.66-0.97; P = 0.027). Furthermore, statin use in patients with VTE was also found to be associated with a lower risk of all-cause mortality (adjusted HR: 0.65, 95% CI: 0.56-0.77), and possibly an even lower risk of bleeding (adjusted HR: 0.88, 95% CI: 0.73-1.07), albeit not statistically significant. Conclusion: Statins have the potential to reduce recurrent events among patient with VTE. Randomized clinical trials to better explore the effect of statins in secondary prevention of VTE are warranted."

基金机构：National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81470583]

基金资助正文：This work was supported by a grant from the National Natural Science Foundation of China (No. 81470583).